205 related articles for article (PubMed ID: 31858714)
1. Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.
Sillen M; Weeks SD; Zhou X; Komissarov AA; Florova G; Idell S; Strelkov SV; Declerck PJ
J Thromb Haemost; 2020 Mar; 18(3):681-692. PubMed ID: 31858714
[TBL] [Abstract][Full Text] [Related]
2. Structural Insights into the Mechanism of a Nanobody That Stabilizes PAI-1 and Modulates Its Activity.
Sillen M; Weeks SD; Strelkov SV; Declerck PJ
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824134
[TBL] [Abstract][Full Text] [Related]
3. Generation and in vitro characterisation of inhibitory nanobodies towards plasminogen activator inhibitor 1.
Zhou X; Hendrickx ML; Hassanzadeh-Ghassabeh G; Muyldermans S; Declerck PJ
Thromb Haemost; 2016 Nov; 116(6):1032-1040. PubMed ID: 27604413
[TBL] [Abstract][Full Text] [Related]
4. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
[TBL] [Abstract][Full Text] [Related]
5. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
6. Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell plasminogen activator and plasminogen activator inhibitor expression.
Lockwood CJ; Krikun G; Papp C; Aigner S; Schatz F
J Clin Endocrinol Metab; 1995 Apr; 80(4):1100-5. PubMed ID: 7714076
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of plasminogen activators in human gingival crevicular fluid.
Brown JM; Watanabe K; Cohen RL; Chambers DA
Arch Oral Biol; 1995 Sep; 40(9):839-45. PubMed ID: 8651888
[TBL] [Abstract][Full Text] [Related]
8. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
9. Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.
Sherman PM; Lawrence DA; Verhamme IM; Paielli D; Shore JD; Ginsburg D
J Biol Chem; 1995 Apr; 270(16):9301-6. PubMed ID: 7721851
[TBL] [Abstract][Full Text] [Related]
10. Additivity in effects of vitronectin and monoclonal antibodies against alpha-helix F of plasminogen activator inhibitor-1 on its reactions with target proteinases.
Komissarov AA; Andreasen PA; Bødker JS; Declerck PJ; Anagli JY; Shore JD
J Biol Chem; 2005 Jan; 280(2):1482-9. PubMed ID: 15516335
[TBL] [Abstract][Full Text] [Related]
11. Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors Type 1 and 2 in human and rhesus monkey fetal membranes.
Liu YX; Hu ZY; Liu K; Byrne S; Zou RJ; Ny T; d'Lacey C; Ockleford CD
Placenta; 1998; 19(2-3):171-80. PubMed ID: 9548184
[TBL] [Abstract][Full Text] [Related]
12. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin.
Arroyo De Prada N; Schroeck F; Sinner EK; Muehlenweg B; Twellmeyer J; Sperl S; Wilhelm OG; Schmitt M; Magdolen V
Eur J Biochem; 2002 Jan; 269(1):184-92. PubMed ID: 11784312
[TBL] [Abstract][Full Text] [Related]
13. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
14. Biphasic regulation of plasminogen activator/inhibitor by LDL in mesangial cells.
Song CY; Kim BC; Hong HK; Kim BK; Kim YS; Lee HS
Am J Physiol Renal Physiol; 2002 Sep; 283(3):F423-30. PubMed ID: 12167592
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator activity during decidualization of human endometrial stromal cells is regulated by plasminogen activator inhibitor 1.
Schatz F; Aigner S; Papp C; Toth-Pal E; Hausknecht V; Lockwood CJ
J Clin Endocrinol Metab; 1995 Aug; 80(8):2504-10. PubMed ID: 7629251
[TBL] [Abstract][Full Text] [Related]
16. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator levels are influenced by location and varicosity in greater saphenous vein.
Shireman PK; McCarthy WJ; Pearce WH; Shively VP; Cipollone M; Kwaan HC; Yao JS
J Vasc Surg; 1996 Nov; 24(5):719-24. PubMed ID: 8918314
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen activator system and its clinical significance in patients with a malignant disease].
Halámková J; Kiss I; Tomásek J; Pavlovský Z; Cech Z; Tutek S; Hanáková L; Moulis M; Penka M
Klin Onkol; 2011; 24(6):418-23. PubMed ID: 22257230
[TBL] [Abstract][Full Text] [Related]
19. Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
Keijer J; Ehrlich HJ; Linders M; Preissner KT; Pannekoek H
J Biol Chem; 1991 Jun; 266(16):10700-7. PubMed ID: 1709939
[TBL] [Abstract][Full Text] [Related]
20. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
